# A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

> **NCT04154189** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 81 (actual)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Ifosfamide
- **DRUG:** Etoposide
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04154189
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-23
- **Primary completion:** 2022-06-22
- **Final completion:** 2023-08-17
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04154189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04154189, "A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04154189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*